RESEARCH USE AND EDUCATIONAL DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
NAD+, or nicotinamide adenine dinucleotide, is a coenzyme involved in cellular metabolism. It is not a peptide. Research on NAD+ includes studies of the molecule itself and studies of precursors such as nicotinamide riboside, or NR, and nicotinamide mononucleotide, or NMN. These interventions cannot be treated as interchangeable. Human experiments have measured changes in metabolites and selected physiological outcomes, but a biochemical change does not automatically demonstrate rejuvenation or broader health benefits. This overview separates three relevant human studies and explains what each can support. [1–3]
NAD+, NR AND NMN ARE DIFFERENT TEST MATERIALS
NAD+ participates in reactions that support cellular function. NR and NMN are related compounds used in pathways that produce NAD+, rather than different names for NAD+ itself. Research involving one of these precursors therefore does not directly establish the effects of administering NAD+. The exact substance, formulation and route used in a study are part of the evidence, not details that can be omitted. [1–3]
Another important distinction is between a metabolite and a clinical outcome. Measuring a chemical in blood, urine or muscle can show that an intervention changes metabolism. It does not necessarily show improved strength, cognition, disease outcomes or lifespan.
A DIRECT NAD+ PILOT MEASURED METABOLIC FATE
Grant and colleagues studied eleven men, with eight assigned to NAD+ and three to a saline control. The investigators measured blood and urine metabolites during and after a supervised six-hour intravenous infusion. Plasma NAD+ did not rise significantly during the first two hours, but increased later; changes in related metabolites and urinary excretion were also observed. [1]
The study helps describe how an administered compound is processed. It was small, brief and focused on metabolic measurements. It did not test whether NAD+ reverses aging, improves athletic performance or produces durable clinical benefits. The observed blood changes also do not, by themselves, show how much intact NAD+ reached particular tissues or cellular compartments.
AN NR TRIAL FOUND BIOCHEMICAL CHANGES WITHOUT BETTER BIOENERGETICS
Elhassan and colleagues conducted a randomized, double-blind crossover trial in twelve older men. After a 21-day NR period, several muscle metabolites related to NAD+ metabolism increased. The researchers also observed changes in gene expression and circulating inflammatory markers. However, the study did not find an improvement in the measured muscle mitochondrial bioenergetics. [2]
Bioenergetics concerns how cells handle energy. This result illustrates why a rise in related metabolites should not be described as proof of increased energy production. The paper concerns NR in a small, selected population over a short period. It cannot validate a separate NAD+ preparation or establish long-term anti-aging effects.
AN NMN TRIAL FOUND A SPECIFIC INSULIN-SENSITIVITY SIGNAL
Yoshino and colleagues studied twenty-five postmenopausal women with prediabetes and overweight or obesity in a ten-week randomized, placebo-controlled trial. NMN was associated with improved muscle insulin sensitivity and changes in muscle insulin signaling. The study did not find corresponding improvements in every metabolic measure, including liver insulin sensitivity or fasting glucose. [3]
This was a specific finding in a specific population. It should not be rewritten as proof that all NAD-related compounds treat diabetes or improve metabolism in everyone. The intervention was NMN, and the study did not establish prevention of diabetes, longer life or equivalent effects from direct NAD+ administration.
WHAT THESE STUDIES MEAN TOGETHER
The human research supports continued investigation of NAD-related metabolism, while showing why biochemical and clinical claims must remain separate. Different studies test different molecules, use different measurements and enroll different participants. Their results cannot be combined into a universal statement that increasing NAD+ improves health.
A reliable research summary identifies the actual intervention and gives negative or unchanged outcomes space alongside positive findings. The studies reviewed here do not establish rejuvenation, broad clinical effectiveness or the safety of independently sourced research products for personal use. Laboratory materials should be interpreted through their own identity and analytical documentation, not assumed equivalent to products used in published trials.
REFERENCES
1. Grant R, Berg J, Mestayer R, et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Frontiers in Aging Neuroscience. 2019;11:257.
https://doi.org/10.3389/fnagi.2019.00257
2. Elhassan YS, Kluckova K, Fletcher RS, et al. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. Cell Reports. 2019;28:1717–1728.e6.
https://doi.org/10.1016/j.celrep.2019.07.043
3. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372:1224–1229.
https://doi.org/10.1126/science.abe9985